Singular Genomics Systems, Inc.
NASDAQ Global SelectTotal Valuation
Singular Genomics Systems, Inc. carries a market capitalization of 50.77M, placing it among publicly traded companies globally. Its enterprise value stands at -24.45M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 50.77M |
| Enterprise Value | -24.45M |
Share Statistics
Singular Genomics Systems, Inc. currently has 2.51M shares outstanding.
| Shares Outstanding | 2.51M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 14.59, and the price-to-book ratio stands at -0.10.
| PE Ratio | N/A |
| PS Ratio | 14.59 |
| PB Ratio | -0.10 |
| P/TBV Ratio | 0.32 |
| P/FCF Ratio | -0.49 |
| P/OCF Ratio | -0.48 |
Enterprise Valuation
| EV / Sales | 427.10 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Singular Genomics Systems, Inc. maintains a current ratio of 7.37, meaning it holds 7.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 40.97, indicating elevated leverage, while an interest coverage ratio of -75.38 demonstrates limited ability to service its debt obligations.
| Current Ratio | 7.37 |
| Quick Ratio | 6.52 |
| Debt / Equity | 40.97 |
| Debt / EBITDA | -0.59 |
| Interest Coverage | -75.38 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -36.65 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.31 |
Stock Price Statistics
Singular Genomics Systems, Inc.'s stock has gained approximately 29.51456% over the past 52 weeks. The 50-day moving average sits at 19.81, while the 200-day moving average is 14.23.
| Beta (5Y) | N/A |
| 52-Week Price Change | 29.51456% |
| 50-Day Moving Average | 19.81 |
| 200-Day Moving Average | 14.23 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Singular Genomics Systems, Inc. generated 2.67M in revenue and converted that into -86.32M in net income, yielding earnings per share of -34.78. EBITDA reached -86.16M, while operating income came in at -93.00M.
| Revenue | 2.67M |
| Gross Profit | -1.35M |
| Operating Income | -93.00M |
| Pretax Income | -86.32M |
| Net Income | -86.32M |
| EBITDA | -86.16M |
| EBIT | -93.00M |
| Earnings Per Share (EPS) | -34.78 |
Balance Sheet
Singular Genomics Systems, Inc. holds 113.83M in cash and equivalents against 50.49M in total debt, resulting in a net debt position of -47.45M. Total book value stands at -400.67M, with working capital of 112.20M providing operational flexibility.
| Cash & Cash Equivalents | 113.83M |
| Total Debt | 50.49M |
| Net Debt | -47.45M |
| Equity (Book Value) | -400.67M |
| Book Value Per Share | -161.43 |
| Working Capital | 112.20M |
Cash Flow
Singular Genomics Systems, Inc. produced -80.43M in operating cash flow over the past twelve months. After subtracting -425,000.00 in capital expenditures, free cash flow totaled -80.86M - equivalent to -32.58 per share.
| Operating Cash Flow | -80.43M |
| Capital Expenditures | -425,000.00 |
| Free Cash Flow | -80.86M |
| FCF Per Share | -32.58 |
Margins
Singular Genomics Systems, Inc. operates with a gross margin of -50.83, reflecting its pricing power and cost economics. The operating margin of -3,488.52 and net profit margin of -3,237.88 provide insight into operational efficiency.
| Gross Margin | -50.83 |
| Operating Margin | -3,488.52 |
| Pretax Margin | -3,237.88 |
| Profit Margin | -3,237.88 |
| EBITDA Margin | -3,231.70 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.39 |
| FCF Yield | -205.71 |
Stock Splits
Singular Genomics Systems, Inc.'s most recent stock split took place on June 26, 2024 with a 30:1 split ratio.
| Last Split Date | 6/26/2024 |
| Split Ratio | 30:1 |
Scores
Singular Genomics Systems, Inc. posts an Altman Z-Score of -3.55, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.55 |